<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3108">
  <stage>Registered</stage>
  <submitdate>15/03/2011</submitdate>
  <approvaldate>15/03/2011</approvaldate>
  <nctid>NCT01316913</nctid>
  <trial_identification>
    <studytitle>24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease</studytitle>
    <scientifictitle>A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>113374</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Pulmonary Disease, Chronic Obstructive</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Chronic obstructive pulmonary disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - GSK573719/GW642444 125/25
Treatment: drugs - GSK573719/GW642444 62.5/25
Treatment: drugs - GSK573719
Treatment: drugs - tiotropium bromide

Experimental: GSK573719/GW642444 125/25 - 125/25 mcg once-daily

Experimental: GSK573719/GW642444 62.5/25 - 62.5/25 mcg once-daily

Experimental: GSK573719 - 125 mcg once-daily

Active Comparator: tiotropium bromide - 18 mcg once-daily


Treatment: drugs: GSK573719/GW642444 125/25
125/25 mcg once-daily

Treatment: drugs: GSK573719/GW642444 62.5/25
62.5/25 mcg once-daily

Treatment: drugs: GSK573719
125 mcg once-daily

Treatment: drugs: tiotropium bromide
18 mcg once-daily

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change From Baseline in Clinic Visit Trough Forced Expiratory Volume in One Second (FEV1) at Day 169 - FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 measurements were taken electronically by spirometry on Days 2, 28, 56, 84, 112, 168, and 169. Baseline is defined as the mean of the assessments made 30 minutes pre-dose and 5 minutes pre-dose on Treatment Day 1. Trough FEV1 is defined as the mean of the FEV1 values obtained at 23 and 24 hours after the previous morning's dosing (i.e., trough FEV1 on Day 169 is the mean of the FEV1 values obtained 23 and 24 hours after the morning dosing on Day 168). Change from Baseline at a particular visit was calculated as the trough FEV1 at that visit minus Baseline. Analysis was performed using a repeated measures model with covariates of treatment, Baseline, smoking status, center group, day, and day by Baseline and day by treatment interactions. ITT=Intent-to-Treat.</outcome>
      <timepoint>Baseline and Day 169</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline (BL) in Weighted Mean (WM) 0-6 Hour FEV1 Obtained Post-dose at Day 168 - FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. The WM FEV1 was derived by calculating the area under the FEV1/time curve (AUC) using the trapezoidal rule, and then dividing the value by the time interval over which the AUC was calculated. The WM was calculated at Days 1, 84, and Day 168 using the 0-6-hour post-dose FEV1 measurements collected on that day, which included pre-dose (Day 1: 30 minutes [min] and 5 min prior to dosing; other serial visits: 23 and 24 hours after the previous morning dose) and post-dose at 15 minutes, 30 minutes, 1 hour, 3 hours, and 6 hours. Change from BL at a particular visit was calculated as WM at that visit minus BL. Analysis was performed using a repeated measures model with covariates of treatment, BL (mean of the two assessments made 30 minutes and 5 minutes pre-dose on Day 1), smoking status, center group, day, and day by BL and day by treatment interactions.</outcome>
      <timepoint>Baseline and Day 168</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  outpatient

          -  signed and dated written informed consent

          -  40 years of age or older

          -  male and female subjects

          -  COPD diagnosis

          -  at least 10 pack-year smoking history

          -  post-albuterol/salbutamol FEV1/FVC ratio of &lt;0.70 and post-albuterol/salbutamol FEV1
             of less than or equal to 70% predicted normal values

          -  score of greater than or equal to 2 on the Modified Medical Resarch Council Dyspnea
             Scale (mMRC)</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  women who are pregnant or lactating or are planning on becoming pregnant during the
             study

          -  current diagnosis of asthma

          -  other respiratory disorders other than COPD

          -  other diseases/abnormalities that are uncontrolled including cancer not in remission
             for at least 5 years

          -  chest x-ray or CT scan with clinically significant abnormalities not believed to be
             due to COPD

          -  hypersensitivity to anticholinergics, beta-agonists, lactose/milk protein or magnesium
             stearate or medical conditions associated with inhaled anticholinergics

          -  hospitalization for COPD or pneumonia within 12 weeks prior to Visit 1

          -  lung volume reduction surgery within 12 months prior to Visit 1

          -  abnormal and clinically significant ECG at Visit 1

          -  significantly abnormal finding from laboratory tests at Visit 1

          -  unable to withhold albuterol/salbutamol at least 4 hours prior to spirometry at each
             visit

          -  use of depot corticosteroids within 12 weeks of Visit 1

          -  use of oral or parenteral corticosteroids, antibiotics for lower respiratory tract
             infection, or cytochrome P450 3A4 inhibitors, within 6 weeks of Visit 1

          -  use of long-acting beta-agonist (LABA)/inhaled corticosteroid (ICS) product if
             LABA/ICS therapy is discontinued withing 30 days of Visit 1

          -  use of ICS at a dose of &gt;1000mcg/day of fluticasone propionate or equivalent within 30
             days of Visit 1

          -  initiation or discontinuation of ICS within 30 days of Visit 1

          -  use of tiotropium or roflumilast within 14 days of Visit 1

          -  use of theophyllines, oral leukotriene inhibitors, long-acting oral beta-agonists, or
             inhaled long-acting beta-agonists within 48 hours of Visit 1

          -  short-acting oral beta-agonists within 12 hours of Visit 1

          -  use of LABA/ICS combination products only if discontinuing LABA therapy and switching
             to ICS monotherapy within 48 hours of Visit 1 for the LABA component

          -  use of sodium cromoglycate or nedocromil sodium within 24 hours of Visit 1

          -  use of inhaled short-acting beta-agonists, inhaled short-acting anticholinergics, or
             inhaled short-acting anticholinergic/short-acting beta-agonist combination products
             within 4 hours of Visit 1

          -  use of any other investigational medication within 30 days or 5 drug half-lives
             (whichever is longer)

          -  long-term oxygen therapy prescribed for &gt;12 hours per day

          -  regular use of nebulized short-acting bronchodilators

          -  participation in acute phase of pulmonary rehabilitation program

          -  known or suspected history of alcohol or drug abse within 2 years prior to Visit 1

          -  anyone affiliated with the investigator site (e.g., investigator, sub-investigator,
             study coordinator, employee of a participating investigator or study site, or
             immediate family member)

          -  previous exposure to GSK573719, GSK573719/GW642444 combination, GW642444 (vilanterol),
             or fluticasone furoate/GW642444 combination</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>872</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/04/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,VIC,WA</recruitmentstate>
    <hospital>GSK Investigational Site - Concord</hospital>
    <hospital>GSK Investigational Site - Cairns</hospital>
    <hospital>GSK Investigational Site - Carina Heights</hospital>
    <hospital>GSK Investigational Site - Kippa Ring</hospital>
    <hospital>GSK Investigational Site - Adelaide</hospital>
    <hospital>GSK Investigational Site - Daw Park</hospital>
    <hospital>GSK Investigational Site - Frankston</hospital>
    <hospital>GSK Investigational Site - Parkville</hospital>
    <hospital>GSK Investigational Site - Nedlands</hospital>
    <postcode>2139 - Concord</postcode>
    <postcode>4870 - Cairns</postcode>
    <postcode>4152 - Carina Heights</postcode>
    <postcode>4021 - Kippa Ring</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>5041 - Daw Park</postcode>
    <postcode>3199 - Frankston</postcode>
    <postcode>3050 - Parkville</postcode>
    <postcode>6009 - Nedlands</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>West Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Ciudad Aut贸noma de Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Mendoza</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Manitoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Newfoundland and Labrador</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Nova Scotia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Regi贸n De Los Lagos</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Regi贸n Metro De Santiago</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Santiago</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Baden-Wuerttemberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bayern</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Brandenburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hessen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Niedersachsen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Nordrhein-Westfalen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Rheinland-Pfalz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Sachsen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Bucheon-si,</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Cheongju, Chungcheongbuk-do</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Daegu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Incheon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Kangwon-do</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seongnam-si, Gyeonggi-do</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Suwon, Kyonggi-do</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Jalisco</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Nuevo Le贸n</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Durango</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Mexico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Constanta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Ploiesti</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Targoviste</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Bloemfontein</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Boksburg North</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Die Wilgers</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Durban</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Gatesville</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Groenkloof</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Pretoria</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Thabazimbi</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>GlaxoSmithKline</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a Phase III multicenter, randomized, double-blind, double-dummy, parallel-group study
      to evaluate the efficacy and safety of two doses of GSK573719/GW642444 Inhalation Powder,
      GSK573719 Inhalation Powder via a Novel Dry Powder Inhaler and tiotropium via HandiHaler when
      administered once-daily over a 24-week treatment period in subjects with chronic obstructive
      pulmonary disease (COPD). Subjects who meet eligibility criteria at Screening (Visit 1) will
      complete a 7 to10 day run-in period followed by a randomization visit (Visit 2) then a
      24-week treatment period. There will be a total of 9 clinic study visits. A follow-up phone
      contact for adverse event assessment will be conducted approximately one week after the last
      study visit (Visit 9 or Early Withdrawal). The total duration of subject participation in the
      study will be approximately 26 weeks. The primary measure of efficacy is clinic visit trough
      (pre-bronchodilator and pre-dose) forced expiratory volume in one second (FEV1) on Treatment
      Day 169. Safety will be assessed by adverse events, 12-lead ECGs, vital signs, and clinical
      laboratory tests.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01316913</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>GSK Clinical Trials</name>
      <address>GlaxoSmithKline</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>